Production baseline verification recorded.
Phase 3 obesity programme initiated in 2026
LATE STAGE PIPELINE
Zenagamtide
Formerly amycretin, this single molecule peptide is being developed in injectable and oral forms.
FDA STATUS
Investigational; not FDA approved
PROFESSIONAL RELEVANCE
Track Phase 3 efficacy, tolerability, oral development and likely differentiation from combination therapies.
Product, formulation and indication
No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.
Status history
Future material changes will be appended with their previous status and source; they will not be silently overwritten.
Verify this record
Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.